More on KLRS
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $9.68 |
|
|||
| Open | $9.46 | ||||
| 52 Wk High | $ | ||||
| 52 Wk Low | $ | ||||
| Day High | $10.42 | ||||
| Day Low | $9.35 | ||||
| P/E | N/A | ||||
| EPS | $ | ||||
| Volume | 41,327 | ||||
- Kalaris to present TH103 phase 1 data at Macula Society meeting
- Kalaris to Present Phase 1 Clinical Data for TH103 at the Macula Society Annual Meeting
- Chardan Capital Markets Starts Kalaris (KLRS) at Buy
- Kalaris (KLRS) PT Raised to $26 at Citizens on 'TH103's differentiated profile'
- Kalaris Therapeutics raises $50 million in private placement
- Kalaris Therapeutics Announces Oversubscribed $50.0 Million Private Placement
- Kalaris reports positive phase 1a data for TH103 eye treatment
- Kalaris Therapeutics Reports Positive Initial Phase 1a Data for TH103 in Treatment-Naïve Neovascular AMD
- Kalaris' (KLRS) TH103 Could Be a Meaningful Player - Citizens
- Kalaris to Present at Noble Capital Markets 21st Annual Emerging Growth Equity Conference
Entities mentioned with KLRS
- Definitive Agreement | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- ARK | View Related Stories »
- Earnings | View Related Stories »
- William Blair | View Related Stories »
- Stifel | View Related Stories »
- Raymond James | View Related Stories »
- Show More...
